Proceedings of the 3rd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/2025.24273

The Treatment of Malaria: A Comparative Study of Artemisinin and Chloroquine

Beile Yan

Hefei No1. High School, Hefei, China
xzqlpmy@163.com

Abstract: Malaria is a parasitic infection transmitted by Anopheles mosquitoes. It's still a significant global health challenge. This paper explores the periodic life, mechanism of transmission and pathogenesis of malaria in detail and complexity. This research is famous for two antimalarial drugs, focus on artemisinin and chloroquine, which explore their respective mechanisms of action, efficacy and limitations in fighting this debilitating disease. By reviewing these years' resources, this study aims to gain insight into the current status and development trends in malaria treatment.

Keywords: Malaria, Artemisinin, Chloroquine

1. Introduction

Malaria, caused by Plasmodium parasites, is one of the oldest and most widespread diseases affecting humans. It is transmitted through the bite of an infected female Anopheles mosquito leads to a series of symptoms, like cerebral malaria and organ failure. The complex life cycle involves humans and mosquitoes of this disease. Therefore, it requires targeted treatment strategies to effectively contain its spread and migrate its impact.

1.1. The lifecycle of malaria

The lifecycle of Plasmodium involves several stages, and each stage has specific challenges to treatment and prevention. The infection begins when a mosquito carrying the parasite injects the parasite into a human host while feeding on blood. These spore into the liver and multiply asymptomatically within liver cells, forming mitogenesis. Then, mitogenesis is released into the blood, infects the erythrocyte, and starts the symptomatic phase of the disease. In red blood cells, parasites replicate asexually, causing the infected cells to rupture and release more solitons into the bloodstream. This cycle of infection and rupture causes the typical symptoms of malaria, including fever, chills and anemia. Some of the metritis differentiate into gametophytes, and it can be eaten by mosquitoes in the subsequent bloodsucking process and continue the life cycle in the insect carrier. [1]

1.2. Mechanisms of infection and transmission

When a sporozoan enters the body through a mosquito bite, the process of infection starts. These spores are highly motile, and it can cross the skin and blood arrive liver. Once inside liver cells, they evade the immune system and experience widespread proliferation; this process is called exocytosis.

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2025.24273

This stage is asymptomatic and can last for several weeks, making Warly detection challenging. When the mitogens are released from the liver into the bloodstream, it will transition into the symptomatic phase. These divisions infect red blood cells and replicate asexually, which leads to the destruction of infected cells and the release of more mitogens. This cycle of infection and rupture causes the typical symptoms, including periodic fever, chills and anemia. When the gametophyte, the sexual reproductive form of the parasite, they are ingested during the blood-sucking process, it will spread to mosquito. In the intestinal tract of mosquitoes, the gametic cells fuse to form a fertilized egg. And the gamete cells fuse to form a fertilized egg, and the fertilized egg develops into ookinetes and then oocysts. The oocysts release spores, and the spores migrate to the mosquito's salivary glands, ready for transmission to a new human host. [2]

1.3. Pathogenesis of malaria

The pathogenesis of malaria involves a complex interplay between the parasite and the host's immune system. Parasites escape immune detection and replicate fast within red blood cells, leading to a range of clinical manifestations from mild symptoms to serious complications. The key mechanism to evade immune detection is through antigenic mutation. The surface protein on the parasite, like PfEMPI, frequently changes frequently, preventing the immune system from producing an effective response. These kinds of evade strategy allows parasites to persist in the host and cause chronic infection. This parasite also induces changes in red cells that promote their survival and replication. For example, infected red blood cells adhere to the walls of blood vessels, lead to isolation and impaired blood flow. This isolation process can lead to serious complications, such as cerebral malaria and organ dysfunction.[3]

2. Treatment of chloroquine

2.1. Accumulation in acidic environment

Chloroquine is weakly alkaline in the blood, and when it enters the red blood cells infected with malaria parasites, it accumulates in the digestive vesicles of the malaria parasites. [4] This digestive bubble is where the malaria parasite digests hemoglobin and has an acidic environment.

2.2. Increase the PH of the digestive vesicle

Chloroquine plays a role in the digestive vesicle and improves the pH of the digestive vesicle. This change will disturb the malaria parasites in the normal process of digesting hemoglobin. [5]

2.3. Destroy the metabolic process

2.3.1. Inhibit heme detoxification

Malaria will produce toxic hemoglobin. In the normal case, the parasite polymerizes heme to form an insoluble malarial pigment, avoiding the toxic of hemoglobin. However, when the hemoglobin increases and digests the value of PH, it will inhibit malarial make the polymerization of heme into malarial pigments.

2.3.2. Interference with nutrient acquisition

Dueto the inability to detoxify heme effectively, the metabolic processes of the malaria parasite are seriously disrupted. It causes the plasmodium can't get the nutrients normally, which in turn effect their survival and reproduction.[6]

DOI: 10.54254/2753-8818/2025.24273

2.4. Have different effects on different phases

2.4.1. Mainly works on the blood stage

Chloroquine mainly acts on the asexual reproduction of malaria parasites in the human blood stage, especially in the early period. The red blood cell and is in the ring phase, the chloroquine works effectually. It can prevent the plasmodium from annular to trophozoite and schizozoite stages and reduce the amount of the plasmodium.

2.5. Has limited effect on other stages

It has little effect on the liver stage of Plasmodium and can't stop the release of Plasmodium from the livers to the blood. At the same time, it has little effect on the gametophytic stage of the malaria parasite and, therefore, does not reduce malaria transmission.

All in all, Chloroquine will destroy the digestion ability of haemoglobin by interrupting the Metabolic processes of protozoa in red blood cells. Thus plays an antimalarial role. With the emergence of resistance to chloroquine, its role in malaria treatment is being changed increasingly.

2.6. Clinical use

Chloroquine was used for both treatment and prophylaxis of malaria. However, due to drug resistance, its use is now limited to areas where the parasite is still sensitive. In the area where chloroquine-resistant malaria is present, it is suggested to use alternative drugs such as sulfamidoxine-pyrimethamine and ethoxylamine Artemisinin-based combination therapies.

For example, in areas where chloroquine resistance is not common, chloroquine is still used to prevent malaria in travellers to malaria-endemic areas.

In pregnant women, chloroquine is regarded as safe and effective for the treatment and prevention of malaria. It is usually used in combination with other medications to ensure it can remove all the parasites and reduce the risk of recurrence. [7]

2.7. Efficacy and resistance

Chloroquine resistance is mainly mediated by mutations in the parasite's PfCRT protein; this protein can reduce the accumulation of drugs in food vacuoles. Most places in the world report chloroquine resistance, which makes chloroquine ineffective in many cases. However, it is still a value choice in places where resistance is not common. Resistance to chloroquine is characterized by reduced parasite sensitivity to the drug, causing the parasites can't be removed completely and increased recurrence rate. The effort against drug resistance includes developing new drugs and combination therapy and the use of alternative treatment options in areas where drug resistance is common. [8]

3. Treatment with artemisinin

Artemisinin treatment is a powerful antimalarial drug are divide from Artemisias annua, it change the treatment of malaria. The Chinese scientist Tu Youyou got the Nobel Prize in Physiology or Medicine in 2015.

3.1. Mechanism of action

Artemisinin and Artemisinin and its derivatives (e.g. artesunate, artemether) play a role in the antimalarial effect by producing reactive oxygen species.

DOI: 10.54254/2753-8818/2025.24273

(ROS). These reactive oxygen species will destroy the parasite's membranes and proteins, causing the parasites to die. Artemisinin has a specific impact on the asexual blood stage of the parasite and makes it a key part of the combination therapy for acute malaria infection. To be more specific, Artemisinin derivatives will be activated by the influence of iron in the parasite's food bubble and form Cytotoxic free radicals. These free radicals attack a lot of goals in the parasite, including its membrane, protein and nucleus. The main target is to be regarded as a hemoglobin degradation pathway in parasites; in this pathway, artemisinin will interfere with the detoxification process of heme, and heme is a toxic byproduct of hemoglobin digestion. By preventing the formation of malarial pigment (a non-toxic crystalline form of heme), artemisinin leads to the accumulation of toxic heme and causes the parasite's death. Artemisinin derivatives also can inhibit the parasite's phosphatidylinositol 3-kinase (PI3K) pathway. This pathway is crucial for the life and republication of parasites. Artemisinin damages the parasite's energy metabolism and causes its death. [9]

3.2. Clinical application

Artemisinin-based combination therapies (ACTs) are the standard treatment for uncomplicated malaria. ACTs will combine Artemisinin derivatives and an adjunct drug (like benfluorene or piperaquine), getting truth of clear parasites quickly. Avoid the appearance of drug resistance and another still can have work on it.

For example, Artesunate-amodiaquine combination therapy is widely used in sub-Saharan Africa. Artesunate can clean the parasites fast, but amodiaquine has a continuous effect on the residual parasites. This combination makes sure to eradicate the parasite completely and reduce the risk of recurrence.

Another commonly used combination therapy is artemether-benfluorenol, it effective against both uncomplicated and severe malaria. Artemether can rapid relief of symptoms. But benfluorenol ensures complete elimination of parasites over a longer period of time.

3.3. Efficacy and drug resistance

Artemisinin derivatives have a strong impact on reducing the burden of parasites and relieving symptoms. However, with the emergence of artemisinin resistance, especially in South East Asia, this poses a major threat to malaria control efforts. Resistance is thought to be mediated by mutations in the parasite's Kelch 13 protein; this mutation can reduce the efficacy of the drug by changing the target of the drug. The performance of artemisinin's drug resistance is delayed clearance of parasites from the bloodstream. With drug resistance, infectious patients require a longer course of treatment, and the risk of recurrence is higher; efforts to combat drug resistance include developing new combination therapies and monitoring resistance patterns to guide treatment decisions.

4. Comparative analysis of artemisinin and chloroquine

Artemisinin derivatives can rapidly reduce the burden of parasites and relieve symptoms effectively, making it an ideal choice for treating acute malaria infections. In comparison, because of the wide drug resistance, the effectiveness of chloroquine has been greatly reduced, limiting its use in many areas.

4.1. Safety and tolerability

Artemisinin and chloroquine are generally well tolerated and almost don't have any serious bad influence. Artemisinin derivatives may cause mild gastrointestinal discomfort, and chloroquine may cause itching and in rare cases, retinal toxicity.

DOI: 10.54254/2753-8818/2025.24273

However, these two kinds of medicine are considered in most patients, including children and pregnant women.

4.2. Drug resistance

Drug resistance has two major problems. The drug resistance of Artemisinin in South East Asia poses a huge threat to malaria control efforts. Chloroquine resistance has been reported in most of the world; it's limited utility in many areas. Developing new drugs and combination therapies is important to overcome drug resistance to ensure effective malaria treatment.

4.3. Cost

Chlorine is relatively cheap and widely available, and many low-income countries can get them. In comparison, artemisinin-based therapies may cost more, although people are making efforts to lower prices and increase accessibility. Providing affordable antimalarial drugs is important for controlling malaria effectively, especially in limited-resource environments.

4.4. Case studies and clinical trials

Many clinical tests have already proven the efficacy and safety of artemisinin-based therapies in the treatment. For example, the Lancet published a study about the efficacy of artesunate-amodiaquine combination therapy in children with uncomplicated malaria in Burkina Faso. The results show this combination therapy is highly effective in reducing parasite burden and relieving symptoms, with a cure rate of over 95%. In 2020, another study in PLOS Medicine compared the efficacy of artemether-benfluorenol and artesunate-amodiquine in the treatment of uncomplicated malaria in Ghana. The result shows that these two kinds of combination therapy are effective, and there were no significant differences in efficacy or safety. [https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04644-w]

4.5. Chloroquine therapy

Although its use has been limited due to drug resistance, Chloroquine therapy is still an important choice in some areas. A study published in the American Journal of Tropical Medicine and Hygiene in 2018 evaluated the efficacy of chloroquine in the treatment of uncomplicated malaria in Malawi. The results show that in areas where drug resistance is not widespread, Chlorquine still affects the cure rate by over 80%. A study published in Malaria Journal in 2023 evaluated the safety and effectiveness of Chloroquine among pregnant women in Sub-Saharan Africa. The research shows that drug resistance is not the problem of areas; Chloroquine is well tolerated, and it is effective in reducing parasite maternal and infant outcomes. [10]

5. Future directions and challenges

5.1. Drug development

The development of new antimalarial drugs is critical to overcoming resistance and improving treatment outcomes. Research endeavors are currently oriented towards discovering potential new targets and formulating therapeutic drugs for resistant parasite strains. For example, in pre-clinical studies, there is potential for compounds designed to target the mitochondria and apicoplasts of the parasite.

DOI: 10.54254/2753-8818/2025.24273

5.2. Combination therapies

Combination therapies like Artemisinin-based combination therapies it is still the cornerstone of malaria treatment. The future purpose is to determine the optimal combination of drugs that can provide quick removal of parasites, avoid drug resistance and reduce negative influence. There are also efforts to create long-acting agents that can ensure effective malaria protection over extended periods of time. [11]

5.3. Prevention and control

In addition to treatment, prevention and control measures are important to relieve diseases. Efforts include developing an effective vaccine, using insecticide-treated nets and implementing vector control strategies. Studies are currently underway to improve the effectiveness and accessibility of these interventions, especially in resource-constrained settings.

5.4. Global health initiatives

Global health initiatives, such as the World Health Organization's (WHO) Global Malaria Programme, play a crucial role in coordinating efforts to combat malaria. The purpose of this action is to reduce the global malaria burden by promoting effective treatment and prevention strategies, strengthening health systems, and mobilizing resources.

6. Conclusion

Malaria is still a huge global health challenge that requires ongoing research and innovation in treatment and prevention. Artemisinin and chloroquine are two kinds of important drugs that have played a key role in controlling malaria. Although artemisinin derivatives can quickly clear parasites and are very effective in treating acute infections, the efficacy of chloroquine is limited by widespread drug resistance. The development of new drugs, combination therapy and prevention strategies are essential to overcome drug resistance, improve treatment outcomes and reduce the malaria burden. Ongoing research and global health initiatives offer hope for a future where is no longer a major threat to global health.

References

[1] *"Human Infections and Detection of Plasmodium knowlesi" PMC, www.ncbi.nlm.nih.gov/pmc/articles/PMC3623376/. Accessed 20 Dec. 2024.*
[2] *Savi, Merveille Koissi. "An Overview of Malaria Transmission Mechanisms, Control, and Modeling" PubMed, pubmed.ncbi.nlm.nih.gov/36649040/. Accessed 20 Dec. 2024*
[3] *"Malaria Pathogenesis" PMC , pmc.ncbi.nlm.nih.gov/articles/PMC5749143/. Accessed 20 Dec. 2024.*
[4] *Schlesinger, P H. "Chloroquine and acid vesicle function" PubMed, pubmed.ncbi.nlm.nih.gov/2675117/. Accessed 20 Dec. 2024.*
[5] *"Chloroquine against malaria, cancers and viral diseases" PMC, www.ncbi.nlm.nih.gov/pmc/articles/PMC7492153/. Accessed 20 Dec. 2024*
[6] *AN, Sharma. "Effect of dietary mannan oligosaccharide supplementation on nutrient digestibility, hindgut fermentation, immune response and antioxidant indices in dogs" PubMed, pubmed.ncbi.nlm.nih.gov/28507766/. Accessed 20 Dec. 2024.*
[7] *White, N J. "The treatment of malaria" PubMed, pubmed.ncbi.nlm.nih.gov/8703186/. Accessed 20 Dec. 2024.*
[8] *Bouyer1, Guillaume. "Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities" Scientific Reports, 6 Aug. 2020, www.nature.com/articles/srep14552. Accessed 20 Dec. 2024.*
[9] *"ScienceDirect" www.sciencedirect.com/science/article/abs/pii/S0163725801001401. Accessed 20 Dec. 2024.*
[10] *"ScienceDirect" www.sciencedirect.com/science/article/pii/S0163725820302023. Accessed 20 Dec. 2024.*

DOI: 10.54254/2753-8818/2025.24273

[11] D, Sinclair. "Drug-Drug Interactions of Artemisinin-Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature" PubMed, 1 June 2022, pubmed.ncbi.nlm.nih.gov/35543380/. Accessed 20 Dec. 2024.